MSD Animal Health has announced that Bravecto Plus has been given a new licence to treat Otodectes Cynotis (ear mites) in cats.

The company points to a study which showed that cats treated Bravecto Plus showed no visible signs of mites at 14 days and 100% efficacy was confirmed at 28 days1. This, says the company, means that Bravecto Plus now gives 12 week control of fleas and ticks, eight week prevention of heartworm disease, treatment of roundworm and hookworm, and treatment of ear mites.

Hannah Newbury, Companion Animal Technical Lead at MSD Animal Health said:  "With 1 in 4 cats in the Big Flea Project study having fleas2, we can conclude that pet owner compliance to parasite prevention is currently poor. 

"This new licence is an important development for vets and cat owners, offering greater convenience, while helping improve flea and tick compliance. Bravecto Plus builds on the qualities of Bravecto and offers vets and cat owners another tool in the fight against an even broader range of potentially harmful parasites. 

"Research by MSD Animal Health shows that 82% of cat owners believe that the ideal flea and tick treatment lasts longer than 2 months3 and vets can offer their cat owners this and more with BRAVECTO PLUS due to its 12 week duration of activity4.  

For further information contact your MSD Animal Health Account Manager.

References

  1. Taenzler et al. Parasites & Vectors 2018;  Efficacy of fluralaner plus moxidectin (Bravecto Plus spot-on solution for cats) against Otodectes cynotis infestations in cats. 11:595.
  2. Abdullah et al.  Parasites & Vectors 2019; Pathogens in fleas collected from cats and dogs:  distribution and prevalence in the UK.
  3. Transdermal Bravecto Market Assessment Study, July 2015.
  4. Bravecto Plus summary of product characteristics (SPC).

Whilst you're here, take a moment to see our latest job opportunities for vet nurses.